<- Go Home

Urologix, Inc.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

Market Cap

$21.00

Volume

35.5K

Cash and Equivalents

$492.0K

EBITDA

-$373.0K

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$5.7M

Profit Margin

47.13%

52 Week High

$0.00

52 Week Low

$0.00

Dividend

N/A

Price / Book Value

-0.00

Price / Earnings

-0.00

Price / Tangible Book Value

-0.00

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-$874.0K

Return on Equity

80.78%

Return on Assets

-7.62

Cash and Short Term Investments

$492.0K

Debt

$5.3M

Equity

-$8.1M

Revenue

$12.0M

Unlevered FCF

$1.2M

Sector

Health Care Equipment and Supplies

Category

N/A

Company Stock Pitches